Clinical Trials Browser

Phase 2/3 × Neoplasms × vedolizumab × Clear all

NCT06337695 2024-04-02

VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer

Phase 2/3 Not yet recruiting

Neoplasm Metastasis, Neoplasms